Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases

Generate Biomedicines signed a multi-target collaboration and license agreement with Zealand Pharma to design multispecific protein therapeutics for obesity and other metabolic diseases using generative AI. Generate will receive $30 million upfront, up to $35 million in early preclinical milestones, and total milestones of nearly $1.2 billion plus tiered royalties for two initial programs, with an option to add a third.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.